Cell-based studies (in vitro and in vivo) and clinical validations were used to address physiologic relevance.<h4>Results</h4>Inactivation of BCL-XL, but not BCL-2, led to fitness defects in renal cancer cells, and sensitized them to chemotherapeutics. This evidence concerns the gene BCL2L1 and renal carcinoma.